Dr. John M. Mccarty, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 113
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: Icahn School of Medicine at Mount Sinai
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
VA license 0101053968
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medical College of Virginia Hospitals Richmond, VA
- Vcu Health Tappahannock Hospital Tappahannock, VA
Medical groups
- Mcv Associated Physicians (1,807 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 113
- Services billed
- 586
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 289 | 49 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 109 | 31 |
| Established patient office or other outpatient visit, 30-39 minutes | 40 | 28 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 31 | 27 |
| Established patient office or other outpatient visit, 40-54 minutes | 29 | 22 |
| Hospital discharge day management, more than 30 minutes | 26 | 21 |
| Molecular pathology procedure; physician interpretation and report | 23 | 13 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 22 | 16 |
| Flow cytometry technique for dna or cell analysis, 2 to 8 markers | 19 | 19 |
| Established patient office or other outpatient visit, 20-29 minutes | 12 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Richmond, VA | 16 |
| Lenalidomide | 15 |
| Pantoprazole Sodium Other prescribers in Richmond, VA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 18 payments worth $24,857 in total to this clinician.
| Kite Pharma, Inc. | $24,312 |
|---|---|
| National Marrow Donor Program | $325 |
| Incyte Corporation | $135 |
| AstraZeneca Pharmaceuticals LP | $43.25 |
| Genetix Biotherapeutics Inc | $41.64 |
| Consulting Fee | $13,730 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $9,540 |
| Food and Beverage | $1,117 |
| Travel and Lodging | $427 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Kite Pharma, Inc. May 4, 2025 | Consulting Fee Yescarta · CELLT Company’s description;4099278;GTF;10758078 | $13,730 |
| Kite Pharma, Inc. Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty) Yescarta · CELLT Company’s description;4265781;AHM;10758078 | $6,890 |
| Kite Pharma, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) Yescarta · CELLT Company’s description;4253695;AHM;10758078 | $2,650 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099404;GTF;10758078 | $427 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $94,737 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
Kite Pharma, Inc. - A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
Celgene Corporation · Completed · NCT03575351 - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
Celgene Corporation - A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
National Marrow Donor Program - Prospective, Multicenter, Observational Registry to Describe the Treatment of Multiple Myeloma with CAR-T and other B-Cell Maturation Antigen (BCMA)- Targeted Therapies in a Real-World Clinical Practice Setting in the…
Janssen Research & Development, LLC - Facilitating Activation of Study Trials (FAST)
National Marrow Donor Program
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.